m3's

Latest Medical News

Researchers Develop Modified Antibiotic 60 Times More Effective Against H. pylori

GASTROENTEROLOGY

Researchers Develop Modified Antibiotic 60 Times More Effective Against H. pylori

This article was translated using machine translation.

A research team at the Technical University of Munich (TUM) has developed a chemically modified antibiotic that demonstrates up to 60 times greater efficacy against Helicobacter pylori than the current standard treatment, according to a study published in Nature Microbiology.

H. pylori infects approximately 43% of the global population. Chronic infection can cause persistent gastric inflammation, peptic ulcers, and is a well-established risk factor for gastric cancer. Treatment has historically relied on metronidazole, but rising antibiotic resistance has increasingly limited its effectiveness, often requiring escalating doses and multi-drug regimens.

The TUM team, led by Professor Stephan A. Sieber of the Chair of Organic Chemistry II, first investigated metronidazole’s mechanisms of action in detail. Beyond its established role in inducing oxidative stress within the bacterium, the researchers identified two additional protein targets: an enzyme involved in neutralising reactive oxygen species, and a protein that repairs oxidative damage. This dual mechanism provides a more complete picture of how the antibiotic acts against H. pylori.

Building on these findings, the researchers synthesised ether derivatives of metronidazole, structurally modified variants with enhanced binding affinity for both target proteins. In laboratory experiments, the new compound showed up to 60-fold greater potency against standard H. pylori strains, and retained strong activity against resistant strains. No significant increase in toxicity towards human cells was observed.

In a murine model, the compound achieved complete eradication of H. pylori at low doses, with less disruption to the gut microbiome compared to conventional therapy. The authors note that clinical trials in humans are required before the compound can be considered a confirmed therapeutic advance.

Source: Fiedler M. et al., Metronidazole and ether derivatives target Helicobacter pylori via simultaneous stress induction and inhibition, Nature Microbiology (2026). DOI: 10.1038/s41564-026-02291-w

Participate in Paid Gastroenterology Surveys

Leave a Reply

Nature Microbiology study from Technical University of Munich shows a modified antibiotic is far more effective against H. pylori.

New to Healthcare Market Research?

Disclaimer:
“Latest Medical News” is a news aggregation page. We do not create, own, or claim rights to the news content featured on this site. All articles and materials belong to their respective publishers and authors. We are not responsible for the accuracy, completeness, or reliability of the content provided by third-party sources.

Discover more from M3 Global Research Blog

Subscribe now to keep reading and get access to the full archive.

Continue reading